Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Prospective Cohort Study of Molecular Residual Disease (MRD) in Stage I-III Surgically Resectable Colon Adenocarcinoma Harboring Oncogenic Driver Mutations

NCT07795528 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07795528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07795528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Prospective Cohort Study of Molecular Residual Disease (MRD) in Stage I-III Surgically Resectable Colon Adenocarcinoma Harboring Oncogenic Driver Mutations
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Recruiting
Start date
August 14, 2026
Completion date
December 31, 2030
Enrollment
392 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon adenocarcinoma, stage i colon cancer, stage ii colon cancer, stage iii colon cancer